TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8625493

Group type: COMPARATOR
Intervention: Diet B (6 day standard diet avoiding well‐known dietary inducers and inhibitors of CYP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diet C (12 day dietary supplement to the standard diet of 500 g/day broccoli)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diet A (customary home diet)
Number of subjects: 16
Study: 1453032

Group type: EXPERIMENTAL
Intervention: Metronidazole (1000 mg)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 3894277

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (14 mg/m2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bisantrene (260 mg/m2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Doxorubicin (cross-over response)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (cross-over response)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bisantrene (cross-over response)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All agents
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mitoxantrone and Bisantrene
Number of subjects: 150
Study: 31266709

Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 0
Study: 28181386

Group type: EXPERIMENTAL
Intervention: In-home rehabilitation (physical treatment program once a week and basic nursing care)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-rehabilitation group (basic in-home nursing care)
Number of subjects: 200
Study: 26047392

Group type: COMPARATOR
Intervention: Nefopam-based PCA (N group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Fentanyl-based PCA (F group)
Number of subjects: 94
Study: 23501976

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 3787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3787
Study: 21790771

Group type: EXPERIMENTAL
Intervention: Sedation with xylazine (0.5 mg/kg bwt, iv)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No sedation (control)
Number of subjects: 6
Study: 19361725

Group type: EXPERIMENTAL
Intervention: Jig exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stretching movements
Number of subjects: 10

Group type: COMPARATOR
Intervention: No exercise (control period)
Number of subjects: 10
Study: 16729229

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (diagnostic angiography)
Number of subjects: 34
Study: 15569584

Group type: EXPERIMENTAL
Intervention: Exposure to televised alcohol commercials (measured by viewing television programs containing alcohol commercials)
Number of subjects: 0
Study: 11237056

Group type: EXPERIMENTAL
Intervention: Idarubicin (12 mg/m2/day for 3 days)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Daunorubicin (60 mg/m2/day for 3 days)
Number of subjects: 293
Study: 9552042

Group type: COMPARATOR
Intervention: CC arm (Carboplatin and Cisplatin)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: CCI arm (Carboplatin, Cisplatin, and Ifosfamide)
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: CCI arm
Number of subjects: 529

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 529
Study: 7801618

Group type: EXPERIMENTAL
Intervention: HPA-1bvar platelets
Number of subjects: 0
Study: 3286068

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1 g, 3 times daily for 10 days
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 89
Study: 29875024

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT) guided by esophageal Doppler monitoring
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard hemodynamic management
Number of subjects: 90
Study: 28651612

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Patient Navigation with Contingency Management (PN + CM)
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Combined (PN and PN + CM)
Number of subjects: 790
Study: 26102552

Group type: EXPERIMENTAL
Intervention: Phytopharmaceutical with Ageratina pichinchensis extract at 5%
Number of subjects: 56

Group type: COMPARATOR
Intervention: Triamcinolone at 0.1%
Number of subjects: 56
Study: 23178173

Group type: EXPERIMENTAL
Intervention: Binge instruction
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non-binge instruction
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 10
Study: 21770897

Group type: EXPERIMENTAL
Intervention: L-carnitine (0.05 g/kg) administered with a rapid infusion diluted in 250 ml of saline solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 19716456

Group type: EXPERIMENTAL
Intervention: FluBlok-45 (45 microg rHA/antigen)
Number of subjects: 156

Group type: COMPARATOR
Intervention: TIV (7.5 microg HA/antigen)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: FluBlok-45
Number of subjects: 156

Group type: COMPARATOR
Intervention: TIV (15 microg HA/antigen)
Number of subjects: 156
Study: 16980000

Group type: EXPERIMENTAL
Intervention: High-dose TMP/SXT (320/1600 mg, daily in two divided doses)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Low to moderate doses of TMP/SXT (either 80/400 mg or 160/800 mg, daily)
Number of subjects: 95
Study: 15250200

Group type: EXPERIMENTAL
Intervention: Compound salvia pellet (CSP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nitrate ester preparation
Number of subjects: 17
Study: 11059223

Group type: EXPERIMENTAL
Intervention: Combination therapy with V.D3 and etidronate (group B)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Monotherapy with active vitamin D3 (group A)
Number of subjects: 25
Study: 9493666

Group type: EXPERIMENTAL
Intervention: Movement detectors (pedometers) in COPD patients
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nasal nocturnal mechanical ventilation (NMV) in chronic respiratory failure patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 75
Study: 8418608

Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg per day administered once daily)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Amoxicillin (40 mg/kg per day administered in three divided doses)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 201
Study: 3614304

Group type: EXPERIMENTAL
Intervention: Calcium acetate (500 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Calcium lactate (500 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Calcium gluconate (500 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Calcium citrate (500 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (500 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whole milk (500 mg)
Number of subjects: 8
Study: 29596724

Group type: EXPERIMENTAL
Intervention: A Woman's Path to Recovery (WPR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 66
Study: 26748220

Group type: EXPERIMENTAL
Intervention: EUS-BD (n=34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: PTBD (n=32)
Number of subjects: 66
Study: 24682910

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 9
Study: 22995802

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg daily (A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg daily (V)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg + Valsartan 160 mg daily (A+V)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All subjects (combined)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Aliskiren (A) and Aliskiren + Valsartan (A+V)
Number of subjects: 33
Study: 20799599

Group type: EXPERIMENTAL
Intervention: Increased price of direct hospital outpatient visits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control district (no intervention)
Number of subjects: 0
Study: 19080096

Group type: EXPERIMENTAL
Intervention: BIS monitoring during intravenous anesthesia with remifentanil and propofol
Number of subjects: 40
Study: 17043181

Group type: EXPERIMENTAL
Intervention: Subcuticular running polyglactin 910 sutures left in place
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Subcuticular running polypropylene sutures left in place
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Subcuticular running polypropylene sutures removed after 14 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Simple running polypropylene sutures removed after 14 days (Control)
Number of subjects: 36
Study: 12723685

Group type: EXPERIMENTAL
Intervention: Modified parcellation method using successive fuzzy c-means (sFCM) and boundary-detection algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional FCM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed method (sFCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 0
Study: 10795438

Group type: EXPERIMENTAL
Intervention: Teachers group (students receiving education through trained teachers)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Lecture group (students receiving health education lecture by health staff)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 385
Study: 9068739

Group type: EXPERIMENTAL
Intervention: benzoyl peroxide 5%/erythromycin 3% gel
Number of subjects: 72

Group type: COMPARATOR
Intervention: erythromycin 4%/zinc 1.2% solution
Number of subjects: 72
Study: 8147168

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxytocin (control group)
Number of subjects: 0
Study: 3535492

Group type: EXPERIMENTAL
Intervention: Oral capsules of potassium metabisulfite
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Double-blind rechallenge with metabisulfite capsules
Number of subjects: 203
Study: 30781998

Group type: EXPERIMENTAL
Intervention: Instrument-based vision screening
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Nonparticipating practices (Control)
Number of subjects: 1000
Study: 28520883

Group type: EXPERIMENTAL
Intervention: Isotonic fluids (NaCl 0.9% in glucose 5% supplemented by 40 mmol litre ‐1 of potassium chloride)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hypotonic fluids (NaCl 0.32% in glucose 5% containing 26 mmol litre ‐1 of potassium)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isotonic fluids
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hypotonic fluids
Number of subjects: 12
Study: 25565530

Group type: EXPERIMENTAL
Intervention: Five successive repeated breath hold maximal efforts (RBHE) separated by 2-min intervals; performed by the NBH group for 14 days.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (CBH) with no training; HCVR test performed before and after the intervention.
Number of subjects: 2
Study: 23280226

Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fructose ingestion
Number of subjects: 20
Study: 21601319

Group type: EXPERIMENTAL
Intervention: Early Enteral Nutrition (EEN)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control management (nil by mouth and IV fluid)
Number of subjects: 121
Study: 18674932

Group type: EXPERIMENTAL
Intervention: Autologous conditioned serum (ACS)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Hyaluronan (HA)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 376
Study: 16769949

Group type: EXPERIMENTAL
Intervention: Ictal eye closure in patients with PNES
Number of subjects: 208

Group type: COMPARATOR
Intervention: Ictal eye opening in patients with epileptic seizures (ES)
Number of subjects: 208
Study: 15580212

Group type: EXPERIMENTAL
Intervention: Systemic hypothermia
Number of subjects: 26
Study: 11393872

Group type: EXPERIMENTAL
Intervention: 100-hour rule waiver
Number of subjects: 2
Study: 9246276

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous propofol anaesthesia
Number of subjects: 20
Study: 8281587

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rectal indomethacin 100 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31083195

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with determination of platelet function
Number of subjects: 156
Study: 28441583

Group type: EXPERIMENTAL
Intervention: Active rTMS combined with paroxetine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham rTMS combined with paroxetine
Number of subjects: 43
Study: 26043354

Group type: EXPERIMENTAL
Intervention: VA bursts present in patients
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: VA bursts
Number of subjects: 196
Study: 23871109

Group type: EXPERIMENTAL
Intervention: Educational Material group (EDUC)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Exposure group (EXPO)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 218
Study: 21914062

Group type: EXPERIMENTAL
Intervention: lamivudine, stavudine and nevirapine
Number of subjects: 389
Study: 19783710

Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg/d for 11 days + Warfarin 30 mg on day 5
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin 30 mg alone on day 1
Number of subjects: 12
Study: 17357336

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg 'on-demand'
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg in four-week courses during a relapse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 60
Study: 12727707

Group type: EXPERIMENTAL
Intervention: DHA, 2 g/day for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 36
Study: 10987586

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 3171
Study: 8842054

Group type: EXPERIMENTAL
Intervention: Nadolol 160mg tablet (Zenith‐Goldline Pharmaceuticals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol 40mg tablet (Zenith‐Goldline Pharmaceuticals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol 40mg tablet (80mg dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corgard 40mg and 160mg tablets (Bristol‐Meyers Squibb)
Number of subjects: 0
Study: 1386272

Group type: EXPERIMENTAL
Intervention: Zoladex (goserelin)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Stilboestrol (3 mg/day)
Number of subjects: 250
Study: 6100938

Group type: EXPERIMENTAL
Intervention: High carbohydrate-high fibre diet (HC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Reinforced low carbohydrate diet (LC)
Number of subjects: 15
Study: 31630485

Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 distal gastrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard Operation Procedure of Laparoscopic D2 Distal Gastrectomy
Number of subjects: 0
Study: 29110384

Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 27704313

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg every week (QW) for 12 weeks, then all patients received etanercept 50 mg QW through week 24
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 24660874

Group type: EXPERIMENTAL
Intervention: Home visit intervention (n = 179)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (n = 181)
Number of subjects: 360
Study: 22926607

Group type: EXPERIMENTAL
Intervention: oral CYT + O3FA (2 g O3FA twice a day, 1 g CYT twice a day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: placebo + O3FA (2 g O3FA twice a day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo + placebo control
Number of subjects: 45
Study: 20457540

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 50

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 50
Study: 18796095

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40KD) plus ribavirin (1,000/1,200 mg/day)
Number of subjects: 555
Study: 15654292

Group type: EXPERIMENTAL
Intervention: Mecamylamine (15 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mecamylamine (7.5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12144941

Group type: EXPERIMENTAL
Intervention: Hexarelin (2.0 microg/kg, i.v.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: GHRH (2.0 microg/kg, i.v.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Recombinant human GH (10.0 microg/kg, i.v.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10560994

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8532260

Group type: EXPERIMENTAL
Intervention: Commercially available probe covers
Number of subjects: 360

Group type: COMPARATOR
Intervention: Condoms
Number of subjects: 360
Study: 6687610

Group type: EXPERIMENTAL
Intervention: Type A subjects during socioeconomic exchanges
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aggressive interactions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Type A and Type B subjects
Number of subjects: 48
Study: 31288901

Group type: EXPERIMENTAL
Intervention: Ilaprazole
Number of subjects: 330

Group type: COMPARATOR
Intervention: Esomeprazole
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Ilaprazole and Esomeprazole
Number of subjects: 330
Study: 30567487

Group type: EXPERIMENTAL
Intervention: 3-pair micro-hole catheter (Contiplex, BRAUN®, 20G - 400 mm)
Number of subjects: 80

Group type: COMPARATOR
Intervention: End-hole catheter (Silverstim VYGON®, 20G - 500 mm)
Number of subjects: 80
Study: 27544861

Group type: EXPERIMENTAL
Intervention: Lipase-catalyzed hydrolysis and esterification reactions using Palatase 20000L
Number of subjects: 0
Study: 24962086

Group type: EXPERIMENTAL
Intervention: Protocolized model of antidepressant care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Model relying on clinical acumen of trained providers
Number of subjects: 150
Study: 22564206

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral (CB) intervention
Number of subjects: 341

Group type: COMPARATOR
Intervention: Brochure control
Number of subjects: 341

Group type: COMPARATOR
Intervention: Bibliotherapy
Number of subjects: 341
Study: 19512961

Group type: EXPERIMENTAL
Intervention: Methylphenidate extended release (OROS MPH)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17197465

Group type: EXPERIMENTAL
Intervention: PAx (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: PLMA (n=50)
Number of subjects: 100
Study: 15201697

Group type: EXPERIMENTAL
Intervention: Diazoxide (DZX) 1.5 mg/kg infused intravenously in 5 min followed by a 5‐min washout before cardiopulmonary bypass.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received placebo infusion.
Number of subjects: 40
Study: 11102590

Group type: EXPERIMENTAL
Intervention: Testosterone implants (800-1200 mg every 3 months)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Testosterone implants (800 mg) with finasteride (5alpha-reductase inhibitor)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (for comparison with finasteride)
Number of subjects: 29
Study: 9519504

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg once daily
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study: 8165591

Group type: EXPERIMENTAL
Intervention: Isotretinoin (40 mg) administered in the morning and evening for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3080694

Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone (TRH) 150 mg IM daily for 2 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3051985

Group type: EXPERIMENTAL
Intervention: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Reperfusion (both APSAC and streptokinase)
Number of subjects: 240
Study: 31454493

Group type: EXPERIMENTAL
Intervention: Automatic Quality Control System (AQCS)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Control group (routine colonoscopies without AQCS)
Number of subjects: 659
Study: 30644815

Group type: EXPERIMENTAL
Intervention: Personalized treatment involving percutaneous ablation for risk factors for worsening CKD
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: Biopsy or active surveillance for growth
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Routine partial nephrectomy (PN)
Number of subjects: 1000000

Group type: EXPERIMENTAL
Intervention: MRI guidance for active surveillance
Number of subjects: 1000000
Study: 28628707

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure reduction (systolic BP target <140 mm Hg)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard blood pressure reduction (systolic BP target <180 mm Hg)
Number of subjects: 133
Study: 26275652

Group type: EXPERIMENTAL
Intervention: Di Huang Yin Zi (DHYZ)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22466697

Group type: EXPERIMENTAL
Intervention: cLkF (Leukocyte filtration of blood cardioplegia)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard cold blood cardioplegia (S-Group)
Number of subjects: 30
Study: 21518437

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Marijuana use
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Multi-substance use
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 145
Study: 19233936

Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy (TLT)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 660